The Hyderabad-based firm and its subsidiary, Promius Pharma LLC have filed three new drug applications with the US Food and Drug Administration (USFDA), Dr Reddy's Laboratories Ltd said in a statement.

The three NDAs - DFD-01, DFD-09, and DFN-11, come from Dr Reddy's proprietary products group, which is focused on developing and commercialising therapies in dermatology and neurology, it added.
"These products potentially represent new, compelling options for specific segments of patients suffering from Psoriasis, Rosacea and Migraine," Dr Reddy's Executive Vice President of Proprietary Products Raghav Chari said.

They are also the first of a large basket of products targeting conditions predominantly treated by the medical dermatologist and neurologist, he added.
"By focusing exclusively on these two specialty therapeutic areas, we intend to build a leading presence in them over time," Chari said.

Upon approval, the products will be commercialised by Promius Pharma, the company said. Dr Reddy's Laboratories shares on Tuesday ended at Rs 3,678.45 apiece on the BSE, down 0.02 percent from previous close.

Latest News  from Business News Desk